PromarkerD US reimbursement price & Aus regulatory decision
Filed with ASX · · 3 pages · English
Centers for Medicare & Medicaid Services (CMS) list PromarkerD predictive test for diabetic kidney disease and assign payment rate of US$390.75 in the United States CMS is the single largest payer for health care in the United States, with Medicare and Medicaid collectively responsible for 42 per cent of healthcare spending and providing health coverage to more than 100 million Americans The
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Suspension from Quotation
- New oesophageal cancer test presented at global conference
- OxiDx platform technology secures patent in Japan
- June 2023 Quarterly Activities Report and Appendix 4C
- Sonic Healthcare USA signs licence for PromarkerD in the US
Later from Proteomics International Laboratories
- September 2023 Quarterly Activities Report and Appendix 4C
- Proteomics receives $1.85 million in R&D tax incentive
- US Medicare confirms reimbursement price for PromarkerD
- PromarkerD licence with Omics Global extended to Chile
- December 2023 Quarterly Activities Report and Appendix 4C
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories